Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 29, 2018 - Issue 3
Submit an article Journal homepage
522
Views
23
CrossRef citations to date
0
Altmetric
Other

Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol

Katharina PietschkeDepartment of Dermatology, Eberhard Karls University Tuebingen, Tuebingen, Germany
&
Martin SchallerDepartment of Dermatology, Eberhard Karls University Tuebingen, Tuebingen, GermanyCorrespondence[email protected]
Pages 310-313 | Received 10 Jul 2017, Accepted 24 Jul 2017, Published online: 11 Aug 2017

References

  • Tan J, Schofer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia – the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428–434.
  • Reinholz M, Ruzicka T, Steinhoff M, et al. Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy. J Dtsch Dermatol Ges. 2016;14(Suppl 6):4–15.
  • Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:431–438.
  • Schauber J, Homey B, Steinhoff M. Current insights into the pathophysiology of rosacea. Hautarzt. 2013;64:481–488.
  • Woo YR, Lim JH, Cho DH, et al. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17:E1562.
  • Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 Suppl 1):S15–S26.
  • Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633–641.
  • Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol. 2015;29:2405–2410.
  • Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719–725.
  • Nicholson K, Abramova L, Chren MM, et al. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57:213–221.
  • Charkoudian N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J Appl Physiol (1985). 2010;109:1221–1228.
  • Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53–62.
  • Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009; 55:77–81.
  • Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650–656.
  • Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13:56–61.
  • Cunliffe WJ, Dodman B, Binner JG. Clonidine and facial flushing in rosacea. Br Med J. 1977;1:105.
  • Grosshans E, Michel C, Arcade B, et al. Rilmenidine in rosacea: a double-blind study versus placebo. Ann Dermatol Venereol. 1997;124:687–691.
  • Bernstein JE, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol. 1982;107:59–61.
  • O'Rourke ST. Antianginal actions of beta-adrenoceptor antagonists. Am J Pharm Educ. 2007;71:95.
  • Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol. 2005;53:881–884.
  • Kwon HJ, Suh JH, Ko EJ, et al. Combination treatment of propranolol, minocycline, and tranexamic acid for effective control of rosacea. Dermatol Ther. 2017;30:e12439.
  • Park JM, Mun JH, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea. J Dermatol. 2015;42:64–69.
  • Eggertsen R, Sivertsson R, Andren L, et al. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S97–S100.
  • Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. J Am Acad Dermatol. 2012;67:491–493.
  • Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. Arch Dermatol. 2011;147:1258–1260.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.